The focal segmental glomerulosclerosis (FSGS) treatment market deals with the manufacturing and distribution of therapeutics for a type of renal disease that affects the kidneys' glomeruli. The disease is caused by complications of autoimmune disease, due to genetic factors, infection, and sclerotic diseases. Focal segmental glomerulosclerosis treatment helps manage this condition and slow the progression of the disease. The prescribed therapy includes the administration of corticosteroids that reduce inflammation and immunosuppressive drugs that control the immune system and reduce kidney damage. The rising geriatric population and the prevalence of chronic diseases demand focal segmental glomerulosclerosis treatment.
However, the availability of limited treatment options and expensive therapies limits the adoption of the FSGS treatment by impacting the market. Despite the challenges, the increasing advancements in the research and development of new treatment plans like monoclonal antibodies, genetic therapies, and stem cell therapies are expected to grow the market. Moreover, the rising awareness and education regarding the disease and well-equipped healthcare providers for treating and diagnosing the disease also hit the focal segmental glomerulosclerosis (FSGS) treatment market. In September 2024, Travere Therapeutics received FDA approval for the Filspari, which significantly reduces the protein in the urine and plans for longer-term kidney function outcomes.
Download
Actionable Solutions
